Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

Siba El Elhussein, MD, L. Jeffrey Medeiros, MD, Kirill A. Lyapichev, MD, Stephen K. Gruschkus, PhD MPH, Peng Wei, PhD, Ellen Schlette, MD, Warren Fiskus, BSc,PhD, Rashmi Kanagal-Shamanna, MD, Sanam Loghavi, MD, Hong Yang, MD PhD, Shaoying Li, MD, Jie Xu, MD, Zhenya Tang, MD PhD, Beenu Thakral, MD, Nitin Jain, MD, William G. Wierda, MD PhD, Keyur Patel, MD PhD, Kapil N. Bhalla, MD, Joseph D. Khoury, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143122

Published: 2020

Journal Articles

BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Bernardo H Lara, Christine Birdwell, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-138637

Published: 2020

Journal Articles

Preclinical Efficacy of a Novel Omacetaxine-Based Therapy for AML Expressing Somatic or Germline Mutant RUNX1

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Courtney D. DiNardo, MD MSCE, Christine Birdwell, Bernardo H Lara, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141742

Published: 2020

Journal Articles

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Christine Birdwell, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-140212

Published: 2020

Journal Articles

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Daniel Rivera, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Rashmi Kanagal-Shamanna, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Sherry A. Pierce, BSN, BA, Michael Andreeff, MD PhD, Kapil N. Bhalla, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Tapan M. Kadia, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-142043

Published: 2020

Journal Articles

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-142092

Published: 2020

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Vrajesh Karkhanis, PhD, Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Abhishek Maiti, MBBS, Bernardo H Lara, James V Maher, Isean Bhalla, Nancy Shao, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 3961.

https://doi.org/10.1182/blood-2019-132041

Published: 2019

Journal Articles

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2647.

https://doi.org/10.1182/blood-2019-122477

Published: 2019

Journal Articles

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Blood (2019) 134 (Supplement_1): 735.

https://doi.org/10.1182/blood-2019-122779

Published: 2019

Journal Articles

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 1274.

https://doi.org/10.1182/blood-2019-130783

Published: 2019

Journal Articles

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Christopher B. Benton, MD, William G. Wierda, MD PhD, Prithviraj Bose, MD, Musa E. Yilmaz, MD, Elias J. Jabbour, MD, Steven M. Kornblau, MD, Kapil N. Bhalla, MD, Naveen Pemmaraju, MD, Nitin Jain, MD, Rashmi Malla, RN, BSN, Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 4057.

https://doi.org/10.1182/blood-2018-99-117334

Published: 2018

Journal Articles

Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

Warren Fiskus, BSc, PhD, Christopher Peter Mill, PhD BA, Raffaella Soldi, Roulan Han, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, David N Saenz, Courtney D. DiNardo, MD MSc, Gautam Borthakur, MD, Tapan M. Kadia, MD, Wendy Jin, Thurika Ganesh, Vaishnavi Rao, Joseph David Khoury, MD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2018-99-114198

Published: 2018

Journal Articles

Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells

Christopher Peter Mill, PhD BA, Tianyu Cai, PhD, Warren Fiskus, BSc,PhD, Gautam Borthakur, MD, Steven M. Kornblau, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Agnieszka J Nowak, Dyana T. Saenz, PhD, David N Saenz, Baohua Sun, MD PhD, Thurika Ganesh, Wendy Jin, Vaishnavi Rao, Joseph David Khoury, MD, Yu Shen, Marina Y. Konopleva, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 1351.

https://doi.org/10.1182/blood-2018-99-113976

Published: 2018

Journal Articles

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, PhD, David N Saenz, Raffaella Soldi, Baohua Sun, MD PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Steven M. Kornblau, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Lucia Masarova, MD, Steve Horrigan, Joseph David Khoury, MD, Sunil Sharma, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 177.

https://doi.org/10.1182/blood-2018-177

Published: 2018

Journal Articles

Targeted Therapy for AML Expressing RUNX1 Mutation

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Courtney D. DiNardo, MDMSc, Yimin Qian, PhD, Kanak Raina, PhD, Koichi Takahashi, MD, Tapan Kadia, MD, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 2472.

https://doi.org/10.1182/blood.V130.Suppl_1.2472.2472

Published: 2017

Journal Articles

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, Yimin Qian, PhD, Kanak Raina, PhD, David N Saenz, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1239.

https://doi.org/10.1182/blood.V130.Suppl_1.1239.1239

Published: 2017

Journal Articles

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, BSc,PhD, Kanak Raina, PhD, Yimin Qian, PhD, Andrew Crew, Dyana T. Saenz, PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, David N Saenz, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1265.

https://doi.org/10.1182/blood.V130.Suppl_1.1265.1265

Published: 2017

Journal Articles

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Liang Zhang, MD PhD, Kanak Raina, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Dyana T Saenz, PhD, Christopher P Mill, PhD, Michael Wang, MD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 1058.

https://doi.org/10.1182/blood.V128.22.1058.1058

Published: 2016

Journal Articles

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T Saenz, PhD, Warren Fiskus, PhD, Kanak Raina, PhD, Taghi Manshouri, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Christopher P Mill, PhD, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 747.

https://doi.org/10.1182/blood.V128.22.747.747

Published: 2016

NARROW

Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Preclinical Efficacy of a Novel Omacetaxine-Based Therapy for AML Expressing Somatic or Germline Mutant RUNX1

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias

Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Targeted Therapy for AML Expressing RUNX1 Mutation

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only